Back

Perphenazine-macrocycle conjugates divert Aβ42 towards non-toxic aggregates by monomer sequestration.

Ball, S. R.; Adamson, J. S.; Sullivan, M. A.; Zimmermann, M. R.; Lo, V.; Sanz-Hernandez, M.; Jiang, F.; Kwan, A. H.; Werry, E. L.; Knowles, T. P.; Kassiou, M.; Meisl, G.; Todd, M. H.; Rutledge, P. R.; Sunde, M.

2020-11-17 biophysics
10.1101/2020.11.16.384248 bioRxiv
Show abstract

Alzheimers disease is imposing a growing social and economic burden worldwide and effective therapies are required. Strategies aimed at the removal of fibrillar plaques formed by the amyloid-{beta} peptide have not proved therapeutic and the focus has shifted to approaches that target the cytotoxic oligomeric amyloid-{beta} species that are populated before fibrils are deposited. We have designed and synthesized perphenazine-cyclam conjugates that specifically and rapidly bind to the monomeric form of A{beta}42, reducing the production of both cytotoxic oligomers and amyloid fibrils. We have applied detailed kinetic analysis and NMR spectroscopy to show that the perphenazine-cyclam conjugates divert the A{beta}42 monomer into amorphous aggregates that are not toxic to differentiated SH-SY5Y cells in vitro. Unlike most other amyloid inhibitors studied to date, these conjugates inhibit oligomer and fibril assembly even in the presence of pre-formed fibrillar seeds, demonstrating that they act through a monomer sequestration mechanism. These modular, three-dimensional conjugates therefore effectively prevent monomer-dependent secondary nucleation, the autocatalytic process that generates the majority of toxic oligomers.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.